EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... April 18, 2025 Five Questions With…Stephen. May 5, 2022 Study Suggests Statins May Help Keep Breast Cancer from Spreading to... June 24, 2020 Load more HOT NEWS Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds AI-Based Score as a Selection Tool for Supplemental MRI After Negative... Reunión anual de la American Society of Clinical Oncology de 2023:... LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by...
